Article Details
Retrieved on: 2022-01-18 16:32:25
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The FDA now expects to decide on approval of beti-cel, Bluebird's gene therapy for the blood disorder beta thalassemia, by August 19, the company said ...
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here